EP 0563239 A4 19941012 - A TRUNCATED INTERLEUKIN-1 RECEPTOR GENE FOR THE TREATMENT OF ARTHRITIS.
Title (en)
A TRUNCATED INTERLEUKIN-1 RECEPTOR GENE FOR THE TREATMENT OF ARTHRITIS.
Title (de)
ZERSTÜMMELTES INTERLEUKIN-1-REZEPTOR-GEN ZUR BEHANDLUNG VON ARTHRITIS.
Title (fr)
GENE RECEPTEUR TRONQUE D'INTERLEUKINE-1 UTILISE POUR LE TRAITEMENT DE L'ARTHRITE.
Publication
Application
Priority
- US 63098190 A 19901220
- US 9109231 W 19911209
Abstract (en)
[origin: WO9211359A1] The subject invention concerns a method of using in vivo a gene encoding an extracellular interleukin-1 binding domain of an interleukin-1 receptor that is capable of binding to and neutralizing interleukin-1 which includes employing recombinant techniques to produce a cell line under the control of a suitable eukaryotic promoter having the gene coding for the extracellular interleukin-1 binding domain of the interleukin-1 receptor; and initiating transfection of DNA of the gene by introducing viral particles obtained from the cell line directly into synovial cells lining a joint space of a mammalian host. Alternatively, synovial cells from the patient's joint may be transduced with the retroviral vector carrying the therapeutic gene and a selectable marker for selection of only transduced cells, and the now therapeutic autologous cells may be introduced back into the joint by transplantation. Additionally, a method of preparing a gene encoding an extracellular interleukin-1 receptor binding domain of an interleukin-1 that is capable of binding to and neutralizing interleukin-1 is disclosed. A compound for parenteral administration to a patient in prophylactically or therapeutically effective amounts containing the gene of the invention and a suitable pharmaceutical carrier is also provided.
IPC 1-7
IPC 8 full level
A61K 35/24 (2015.01); A61K 35/32 (2015.01); A61K 35/76 (2015.01); A61K 48/00 (2006.01); A61P 29/00 (2006.01); C07K 14/715 (2006.01); C12N 5/10 (2006.01); C12N 7/00 (2006.01); C12N 15/09 (2006.01); C12N 15/867 (2006.01); A61K 38/00 (2006.01)
CPC (source: EP)
A61P 29/00 (2018.01); C07K 14/715 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C12N 2740/13043 (2013.01); C12N 2740/13045 (2013.01)
Citation (search report)
- [Y] WO 8904838 A1 19890601 - IMMUNEX CORP [US]
- [Y] EP 0318296 A2 19890531 - IMMUNEX CORP [US]
- [Y] P. ROUX ET AL.: "A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 86, no. 23, December 1989 (1989-12-01), WASHINGTON, DC, USA, pages 9079 - 9083
- [Y] T. FRIEDMANN: "Progress toward human gene therapy.", SCIENCE, vol. 244, no. 4910, 16 June 1989 (1989-06-16), WASHINGTON, DC, USA, pages 1275 - 1281
- [A] M. TSUDA ET AL.: "Retrovirus-mediated gene transfer into mouse cerebellar primary culture and its application to the neural transplantation.", BRAIN RESEARCH BULLETIN, vol. 24, no. 6, 1990, pages 787 - 792
- [A] M. ROBERTSON: "Gene therapy. Desperate appliances.", NATURE, vol. 320, 20 March 1986 (1986-03-20), LONDON, GB, pages 213 - 214
- See also references of WO 9211359A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
DOCDB simple family (publication)
WO 9211359 A1 19920709; CA 2098848 A1 19920621; EP 0563239 A1 19931006; EP 0563239 A4 19941012; JP H06504440 A 19940526
DOCDB simple family (application)
US 9109231 W 19911209; CA 2098848 A 19911209; EP 92902630 A 19911209; JP 50285491 A 19911209